company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,879510.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4392127.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5271637.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5271637.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,594.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,594.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5271043.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5271043.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,-940766.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6211809.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6211809.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-12.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-12.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,510669.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:04:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-12.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,806032.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4360908.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5166940.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5166940.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,427.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,427.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5166513.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5166513.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,-940762.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6107275.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6107275.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-11.65
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-11.65
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,524066.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:35:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-11.65
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,965002.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6660903.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7625905.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7625905.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,290577.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,393.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-290184.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7916089.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7916089.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,-940768.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8856857.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8856857.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-16.59
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-16.59
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,533839.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:18:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-16.59
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1057019.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1457887.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2514906.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2514906.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,431877.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,79649.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-352228.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2867134.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2867134.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,2822296.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-44838.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,3763061.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3807899.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-7.13
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-7.13
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,525689.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-7.13
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,972101.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1876218.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2848319.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2848319.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,406598.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,105207.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-301391.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3149710.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3149710.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3149710.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,313588.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3463298.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13250511.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q1,2012-01-01,2012-03-31,2013-04-25 17:01:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1777353.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7423833.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9201186.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9201186.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,327496.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,707.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-326789.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9527975.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9527975.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9527975.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9527975.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.45
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.45
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21034570.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 09:01:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.45
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1494824.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3156011.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4650835.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4650835.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,330955.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,675.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-330280.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4981115.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4981115.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4981115.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4981115.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20800000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20800000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21038008.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q3,2012-07-01,2012-09-30,2013-10-29 16:46:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1824179.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4413016.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6237195.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6237195.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,331769.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,975.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-330794.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6567989.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6567989.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6567989.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6567989.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20000000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.28
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20000000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.28
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19882585.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.28
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2647253.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7370960.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10018213.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10018213.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,327286.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,589.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-326697.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10344910.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10344910.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10344910.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10344910.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,24600000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.42
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,24600000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.42
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,24903774.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q1,2013-01-01,2013-03-31,2014-04-29 16:06:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.42
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4567752.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4567752.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4567752.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2081450.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6326986.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8408436.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3840684.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,385040.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12678.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-372362.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4213046.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4213046.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4213046.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4213046.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26381943.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q2,2013-04-01,2013-06-30,2014-07-29 16:06:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1172268.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1172268.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1172268.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2167234.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11919394.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14086628.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12914360.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,736288.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3152.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-733136.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13647496.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13647496.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13647496.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13647496.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33184322.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q3,2013-07-01,2013-09-30,2014-10-29 16:05:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2072946.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2072946.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2072946.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2537510.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15682355.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18219865.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16146919.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,683609.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1274.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-682335.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16829254.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16829254.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16829254.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16829254.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29400000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29400000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29449716.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3082949.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3082949.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3082949.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3189697.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16383658.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19573355.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16490406.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,575728.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,45124.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-530604.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17021010.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17021010.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17021010.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17021010.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33400000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.51
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33400000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.51
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33200950.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q1,2014-01-01,2014-03-31,2015-04-30 16:35:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.51
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1896705.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1896705.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1896705.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2604898.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15197917.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17802815.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15906110.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,559731.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,88145.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-471586.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16377696.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16377696.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16377696.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16377696.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33400000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.49
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33400000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.49
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33216865.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q2,2014-04-01,2014-06-30,2015-07-29 16:35:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.49
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7766216.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7766216.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7766216.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2853433.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15652879.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18506312.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10740096.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,615938.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,515.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-615423.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11355519.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11355519.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11355519.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11355519.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33400000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.34
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33400000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.34
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33587506.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q3,2014-07-01,2014-09-30,2015-10-22 07:52:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.34
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2470130.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2470130.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2470130.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3428972.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15304546.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18733518.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16263388.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,631603.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,216.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-631387.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16894775.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16894775.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16894775.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16894775.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34100000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.5
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,34100000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.5
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34130901.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.5
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13964000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13964000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13964000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4650000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,26118000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30768000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16804000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,614000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-612000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17416000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17416000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17416000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17416000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42500000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42670632.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 07:31:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5054000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5054000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5054000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5732000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23676000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29408000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24354000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,617000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-615000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24969000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24969000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24969000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24969000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43800000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.57
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43800000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.57
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43686174.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:37:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.57
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2497000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2497000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2497000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5848000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23541000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29389000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26892000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,679000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-679000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27571000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27571000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27571000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27571000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43800000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.63
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43800000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.63
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43910908.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2015.0,Q3,2015-07-01,2015-09-30,2016-10-27 16:31:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.63
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2679000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2679000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2679000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8324000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23529000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31853000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29174000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,330000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,98000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-232000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-29406000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-29406000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-29406000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-29406000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,48200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.61
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,48200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.61
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47853099.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 07:31:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.61
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3420000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3420000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3420000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11988000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16018000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28006000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24586000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,323000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,104000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-219000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24805000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24805000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24805000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24805000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,48600000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.51
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,48600000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.51
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48897740.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 08:11:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.51
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3972000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3972000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3972000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,15021000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21096000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,36117000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32145000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,295000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,128000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-167000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-32312000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32312000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32312000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-32312000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52100000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.62
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52100000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.62
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52072536.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:18:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.62
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-10071000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-10071000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-10071000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,-15923000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,-10852000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-26775000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,16704000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3458000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-355000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4113000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,12591000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,12591000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,12591000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,21117000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8526000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-20598.39
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-20598.39
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,4614.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-20598.39
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22463000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22463000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22463000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7973000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12917000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20890000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1573000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1622000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-30000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1647000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-74000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-74000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-74000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,5720000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5794000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-208.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-208.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27835.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 17:08:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-208.16
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3979000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3979000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3979000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7699000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14075000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21774000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17795000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2369000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-274000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2631000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20426000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20426000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20426000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,5721000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26147000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-884.09
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-884.09
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29575.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 08:18:40+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-884.09
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3191000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3191000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3191000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10304000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10884000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21188000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17997000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2381000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,735000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1639000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19636000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19636000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19636000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,5720000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-25356000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-857.35
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-857.35
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29575.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 08:14:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-857.35
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4231000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4231000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4231000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,37349000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11599000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,48948000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-44717000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1859000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,131000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,27665000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,25937000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18780000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18780000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18780000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,2098000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20878000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,700000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-29.83
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,700000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-29.83
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,715369.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-29.83
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14841000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14841000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7686000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7686000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7155000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,34624000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16129000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,50753000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-43598000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12791000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,210000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,24089000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,11508000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-32090000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32090000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,2658000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-29432000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-29432000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,6200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-4.76
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,6200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-4.76
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,6183540.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q1,2018-01-01,2018-03-31,2019-05-10 16:20:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-4.76
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12022000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12022000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,10989000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,10989000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1033000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,34946000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15813000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,50759000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-49726000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10659000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,63000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2421000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8175000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-57901000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-57901000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,2121000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-55780000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-55780000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,8100000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-6.92
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,8100000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-6.92
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,8059471.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q2,2018-04-01,2018-06-30,2019-08-09 07:40:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-6.92
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,34078000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,34078000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13393000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13393000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20685000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,34287000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13065000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,47352000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26667000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11477000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,248000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,9564000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1665000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-28332000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-28332000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,472000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27860000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27860000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.49
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.49
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11202507.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:58:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.49
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,82069000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,82069000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8989000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8989000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,73080000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,29455000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10402000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,46580000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,25088000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,111525000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-38445000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10847000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,209000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,10214000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-424000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-38869000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-38869000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,-5251000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-44120000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-44120000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,9200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-4.8
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,9200000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-4.8
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,9181668.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-4.8
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14084000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14084000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7365000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7365000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6719000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,25941000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5364000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31305000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24586000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8013000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,187000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,5942000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1884000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26470000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26470000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,-62000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26532000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26532000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.34
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11300000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.34
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11330019.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q1,2019-01-01,2019-03-31,2019-05-10 16:20:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.34
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15955000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15955000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8639000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8639000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7316000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,30932000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3527000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34459000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-27143000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9541000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,210000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,269000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9062000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-36205000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-36205000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,25000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-36180000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-36180000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11800000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.07
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11800000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.07
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11801874.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q2,2019-04-01,2019-06-30,2019-08-09 07:40:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.07
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15870000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15870000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8213000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8213000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7657000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,26417000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4696000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,176725000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,207838000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-200181000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10948000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-7198000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4002000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-14144000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-214325000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-214325000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,943000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-213382000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-213382000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13600000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-15.67
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13600000.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-15.67
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13614986.0
"Melinta Therapeutics, Inc.",MLNT,,0001461993,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:58:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-15.67
